A successful pharma AI project begins with a controlled workflow, not a model demonstration. This tutorial uses regulatory dossier support as the example, but the same method applies to clinical study summaries, pharmacovigilance literature triage, CMC knowledge retrieval, and quality investigation assistance.
Before implementing Generative AI Use Cases, define exactly what the system may produce and who is responsible for approving it. For example, a regulatory assistant might draft an eCTD section outline from approved source documents while remaining prohibited from inventing interpretations, changing data, or publishing submission-ready content.
Step 1: Map the current workflow
Document the process from source evidence to approved output. For an IND clinical summary, that could include retrieval of the protocol, statistical analysis plan, tables, listings, figures, and clinical study report, followed by medical writing and quality review.
Capture a measurable baseline:
- Time spent locating authoritative documents
- Number of review cycles
- Frequency of version-control errors
- Time required to verify citations and numerical claims
- Defects found during publishing or submission readiness checks
This baseline prevents the team from declaring success merely because generated prose appears quickly. The relevant outcome is whether the complete, reviewed process becomes faster and remains inspection-ready.
Step 2: Establish the approved evidence boundary
Create a source inventory and classify each repository by authority, currency, ownership, and access restrictions. Separate final clinical documents from drafts, approved analytical methods from superseded versions, and released batch records from working copies.
For retrieval-augmented generation, preserve useful metadata such as study identifier, product, indication, document status, effective date, section, and data owner. Apply role-based access before retrieval so the model never receives content the user is not permitted to view.
Generative AI Use Cases involving patient data, safety narratives, or confidential molecular structures also require privacy and security controls. Minimize data sent to the model, encrypt it in transit and at rest, define retention rules, and test for leakage across users or projects.
Step 3: Design the generation contract
A generation contract is a precise specification for input, output, and refusal behavior. Require the system to cite supporting passages, state when evidence conflicts, preserve scientific units, and avoid extrapolating beyond retrieved material.
A dossier-support contract might require this structure:
- Requested eCTD section and intended audience
- Evidence table listing source documents and versions
- Draft text with sentence-level citations
- Unresolved discrepancies and missing evidence
- Reviewer checklist and approval state
Keep prompts and templates under version control. A small change in instructions can alter output quality, so changes should be assessed with the same seriousness as updates to retrieval logic or model configuration.
Step 4: Build a representative evaluation set
Create test cases from real work, including difficult examples. Include inconsistent terminology, scanned tables, amended protocols, missing values, and documents with similar titles but different approval states.
Evaluate factual accuracy, citation correctness, completeness, refusal behavior, and reviewer effort. When generated material enters editorial workflows, AI writing detection systems may provide an additional review signal, although they cannot replace provenance records or human verification.
Challenge the system with adversarial instructions embedded in documents and requests that cross authorization boundaries. For GxP-relevant use, record expected results, acceptance criteria, test evidence, and deviations. Generative AI Use Cases should not advance because they perform well on a few curated examples.
Step 5: Pilot with human checkpoints
Run the tool in parallel with the established process. Regulatory affairs, quality assurance, information security, data owners, and end users should agree on escalation routes before the pilot begins.
Require reviewers to classify corrections. Useful categories include unsupported claim, wrong source, outdated source, omitted evidence, numerical error, misleading synthesis, and formatting defect. These labels reveal whether remediation belongs in source governance, retrieval, prompting, model selection, or user training.
Monitor performance after release because document collections, user behavior, and models change. Define triggers for re-evaluation, including repository migrations, new document types, prompt revisions, and model upgrades.
Conclusion
Implementing Generative AI Use Cases in pharma is a lifecycle discipline: map the workflow, govern the evidence, specify behavior, test realistic failures, and retain accountable human review. Organizations assessing Pharmaceutical AI Solutions should treat traceability, validation, and post-release monitoring as core product requirements rather than paperwork added after deployment.
Top comments (0)